Mandibular Advancement Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mandibular advancement devices market size is projected to expand from USD 514.80 million in 2025 and USD 555.06 million in 2026 to USD 808.79 million by 2031, registering a CAGR of 7.82% between 2026 and 2031. This report is segmented by Product Type (Bite, Custom, and Semi-Custom MAD), Application (Obstructive Sleep Apnea, and More), Material (Plastic/Polymer and Metal), End User (Sleep Clinics, and More), Distribution (Hospital/Dental, Retail, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). Market Forecasts are in Value (USD).

Global Mandibular Advancement Devices Market Trends and Insights

Rising Prevalence and Diagnosis of Obstructive Sleep Apnea

OSA remains underdiagnosed in many health systems, even as screening and access to sleep testing improve. Home sleep testing can reduce the distance between suspected symptoms and a formal diagnosis. The American Academy of Sleep Medicine and the American Academy of Dental Sleep Medicine recommend oral appliance therapy for adults with OSA who cannot tolerate CPAP or prefer an alternative treatment. That clinical position provides a defined referral route for the mandibular advancement devices market. A 2026 longitudinal study reported objective mean oral appliance use of 7.05 hours on nights worn during the first 3 months. Greater awareness of snoring as a possible sign of sleep-disordered breathing can also bring people without an OSA diagnosis into dental sleep practices.

Preference for Noninvasive Alternatives to CPAP

CPAP intolerance continues to support the use of oral appliance therapy among eligible patients. The choice is also becoming more relevant for newly diagnosed people who want care that fits home testing and telehealth-enabled pathways. A 2025 pilot randomized trial found that a digitally fabricated MAD delivered a statistically equivalent reduction in apnea-hypopnea index, or AHI, to a traditional monoblock device. The same study found that lower anterior dental pain was significantly reduced with the digital device. A separate 2025 study reported that a precision-custom protocol reduced AHI to below 10 events per hour in 90% of treated patients and achieved a 63% mean AHI improvement from baseline. These findings can support referral relationships that include sleep physicians, pulmonologists, cardiologists, and dentists.

Dental and Temporomandibular Joint Side Effects

Temporomandibular joint discomfort, occlusal changes, and lower anterior tooth pain can limit long-term adherence. A randomized controlled trial followed 65 patients using 2 MAD designs for 12 months. It documented orofacial pain, masticatory muscle tenderness, temporomandibular joint tenderness, and changes in interdental contact. These effects require careful patient selection and regular follow-up by the prescribing clinician. Manufacturers can support prescriber confidence by supplying repositioning tools and by designing appliances that help manage side effects. The mandibular advancement devices market may be constrained where providers lack experience managing these treatment issues.

Other drivers and restraints analyzed in the detailed report include:

• Digitized Customization Through CAD/CAM and 3D Printing
• Expansion of Sleep Clinic and Dental Sleep Medicine Networks
• Uneven Reimbursement and High Custom Device Cost

Segment Analysis

Custom devices held 56.76% of the mandibular advancement devices market share within the product type in 2025. Their position reflects their adjustment capability and their role in physician-referred treatment. Precision-custom therapy reported a 63% mean AHI improvement across patient subgroups in a 2025 study. That evidence supports the use of fitted appliances for patients who need structured clinical care. Semi-custom products provide an intermediate option with more adjustment than bite devices. They can reduce fabrication time and cost, although digital workflows are narrowing the historic price difference with custom products.

Custom devices are forecast to grow at a CAGR of 9.65% through 2031. The mandibular advancement devices industry is moving toward greater use of digital design and additive manufacturing in this category. Bite devices continue to serve over-the-counter, pharmacy, and primary snoring demand. Their simpler form makes them less suited to clinician-led adjustment and ongoing treatment management. Laboratories that use CAD/CAM and 3D printing can challenge specialist brands on production quality. Suppliers are therefore differentiating with adjustment systems, monitoring features, and evidence that supports treatment outcomes.

Obstructive sleep apnea accounted for 45.76% of application revenue in 2025. Its leading position is linked to reimbursement pathways, physician referrals, and established guidance on oral appliance therapy. Mild to moderate OSA is the core setting for many fitted appliances. Patients who cannot tolerate CPAP are also a defined treatment population. The clinical role of the mandibular advancement device market is consequently closely tied to diagnosis, prescribing, and follow-up within sleep medicine.

Primary snoring is forecast to grow at a CAGR of 9.33% through 2031. Digital and direct-to-consumer pathways can make an appliance more accessible before a formal sleep study occurs. The virtual titration model described in the supplied evidence shows how remote care can establish objective improvement for selected mild to moderate OSA patients. Some people seeking treatment for snoring may later receive an OSA diagnosis and enter a higher-acuity care pathway. Temporomandibular joint syndrome and other applications remain smaller, more stable areas that are often served by orofacial pain specialists and orthodontists. A 2026 study also reported reductions in both respiratory events and sleep bruxism episodes during oral appliance therapy.

Complete Report Scope:

• By Product Type
  • Bite MAD
  • Custom MAD
  • Semi-Custom MAD
• By Application
  • Obstructive Sleep Apnea
  • Primary Snoring
  • Temporomandibular Joint Syndrome
  • Other Mandibular Advancement Device Applications
• By Material Type
  • Plastic and Polymer
  • Metal Components
• By Distribution Channel
  • Hospitals and Dental Clinics
  • Retail Pharmacies
  • Online Stores and Pharmacies
• By End User
  • Sleep Clinics
  • Dental Clinics
  • Hospitals
  • Home Care Settings and Individuals
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 43.21% of the global mandibular advancement devices market share in 2025. The United States supports demand through sleep-dental referral networks, commercial insurance coverage, and active device regulation. E0486 provides a billing route for custom-fabricated appliances, although new prior authorization policies can increase administrative work for practices. Canada has variable provincial coverage, while Mexico relies more on private-pay dental demand. The region has competition across specialist device suppliers, laboratory groups, and direct-to-consumer channels.

Europe is the second-largest regional area for these appliances. Germany is a key market because its coverage and clinical guidance support the use of individually fitted devices for eligible people with OSA. The DGSM 2025 S3 guideline positioned individually fitted MADs alongside CPAP as a first-line therapy for mild OSA, defined as AHI 5 to 15. The guideline cited a meta-analysis of 14 randomized controlled trials involving 2,100 participants. It also reported long-term oral appliance compliance of 75% to 85%, compared with 30% to 50% for CPAP users at 6 months. The United Kingdom, Spain, France, and Italy offer additional demand through guided care pathways, dental sleep clinics, specialist availability, and private payer coverage.

Asia-Pacific is forecast to expand at a CAGR of 8.54% through 2031. China, Japan, South Korea, India, and Australia are increasing diagnoses and developing dental sleep medicine capacity. Japan’s aging population, South Korea’s dental technology investment, and Australia’s private dental sector favor premium custom appliances. India and Southeast Asia have earlier-stage reimbursement and fewer specialists, which limits near-term access. Their unmet need and expanding private sleep care create scope for future adoption. The Middle East and Africa, along with South America, remain smaller regions where private sleep clinics and awareness of oral appliance therapy are growing.

List of Companies Covered in this Report:

• Airway Management, Inc.
• Apnea Sciences Corporation
• DynaFlex
• Erkodent Erich Kopp GmbH
• Glidewell
• NDX Keller Dental Lab
• Myerson
• OpenAirway
• Oventus Medical Limited
• ProSomnus Sleep Technologies
• Scheu-Dental GmbH
• SomnoMed Limited
• The Aurum Group
• Tomed GmbH
• Vivos Therapeutics
• Whole You, Inc.
• OravanOSA
• OSCIMED

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support